Articles Archives - Page 170 of 804

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent…

TuesdayMay 28, 2024 9:45 am

Growing EM Applications as America Adopts Ankle Monitors for Asylum Seekers

SuperCom, a global leading provider of traditional and digital identity solutions, is tapping into the growing use cases for electronic monitoring (“EM”) solutions globally New adoption of the technology is seen in a move by the U.S. government to use ankle monitors to also track asylum seekers entering the country to help support and expedite their asylum process For SuperCom, this is a further validation of the value of EM solutions, their versatility and overall effectiveness SuperCom’s management anticipates a growth in the demand for its products as the conversation around these solutions continues to proliferate SuperCom (NASDAQ: SPCB), a…

TuesdayMay 28, 2024 9:00 am

Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA) Grows Asset Portfolio with Additional Claims Acquisition at the Flagship Kenbridge Nickel Project

Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, just acquired additional contiguous claims at its flagship Kenbridge Nickel Project This brings the total coverage to 4,273 ha, with 93 contiguous patents, four mining licenses, and 153 single-cell mining claims The company also announced the commencement of the 2024 baseline field work conducted by Aspen Biological Ltd. These two milestones are a testament to the company’s commitment to creating shareholder value and following through with its plans for the 2024 calendar year Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral and battery…

FridayMay 24, 2024 10:30 am

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), JV Partner Report New Exploration Targets at Storm Project Amid Rising Copper Prices

Preliminary interpretation of initial MLEM survey results indicates new exploration targets highlighting excellent potential to discover additional copper mineralization Copper process projected to continue upward trend Results open “a whole new space for potential discovery,” says Aston Bay CEO As copper prices climb to a 2024 high, Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) is reporting initial results from geophysical activities that are currently underway at its Nunavut-based Storm Copper Project (https://ibn.fm/d5faa). According to the report, preliminary interpretation of the initial moving loop electromagnetic (“MLEM”) survey results indicates several new exploration targets highlighting excellent potential to discover additional copper mineralization.…

FridayMay 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy

Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently…

FridayMay 24, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis

PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide…

ThursdayMay 23, 2024 12:00 pm

DealFlow Events Presents the 5th Annual Reg A & Crowdfunding Conference June 20, 2024

The 5th Annual Reg A & Crowdfunding Conference will take place at New York’s luxurious Westchester Country Club on June 20 The fifth annual conference will play host to investors, entrepreneurs and financiers as we to delve into the latest trends within the equity capital markets industry This year’s conference will feature a number of keynote presentations and speakers, including on topics such as the structuring and efficient marketing of Reg A+ and Crowdfunding deals Learn from (and network with) experts who raise capital with these powerful tools Equity capital markets have long been an attractive source of growth capital…

ThursdayMay 23, 2024 11:15 am

4th Annual Psychedelic Therapeutics and Drug Development Conference Comes to Boston, MA

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking. Specific areas of discussion will include: Targets for novel drug development Toxicology studies and considerations The dosage debate and new evidence Second generation psychedelic drug design FDA regulatory guidance The speaker…

ThursdayMay 23, 2024 10:30 am

DGE 8th Digital Strategy & Innovation for Medical Affairs To Open New Pathways of Transformation

DGE invites medical affairs and healthcare professionals to attend the 8th Digital Strategy & Innovation For Medical Affairs summit in Philadelphia on June 5-6, 2024. Experts attending the conference will offer insights to leverage digital technology for building patient and caregiver relationships, and for maintaining market position. The summit is organized by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotechnology, healthcare, medical devices, and allied industries. The event agenda covers: Incorporating AI into patient outreach Identifying the most important tools…

Site Search

Company Search

Category: Articles